

Publications Related to the AIC Spectrophotometry Facility

2001–2005

2005

1. Witte, R.P. and W.Y.J. Kao, *Keratinocyte-fibroblast paracrine interaction: the effects of substrate and culture condition*. Biomaterials, 2005. **26**(17): p. 3673–3682.
2. Comstock Lindsay, R. and R. Rajski Scott, *Conversion of DNA methyltransferases into azidonucleosidyl transferases via synthetic cofactors*. Nucleic acids research, 2005. **33**(5): p. 1644–52.

2004

1. Witte, R.P., et al., *Analysis of poly(ethylene glycol)-diacrylate macromer polymerization within a multicomponent semi-interpenetrating polymer network system*. J Biomed Mater Res, 2004. **71A**(3): p. 508–18.
2. Weller, R.L. and S.R. Rajski, *Aziridination of g,d-dibromoethyl-2-pentenoate with primary amines: extension of the Gabriel-Cromwell reaction*. Tetrahedron Letters, 2004. **45**(30): p. 5807–5810.
3. Smith, L.J., et al., *Sedative effects and serum drug concentrations of oxymorphone and metabolites after subcutaneous administration of a liposome-encapsulated formulation in dogs*. Journal of Veterinary Pharmacology & Therapeutics, 2004. **27**(5): p. 369–372.
4. McAnulty, J.F., et al., *Suppression of cold ischemic injury in stored kidneys by the antimicrobial peptide bactenecin*. Cryobiology, 2004. **49**(3): p. 230–40.
5. Lee, T.W.-Y. and J.R. Robinson, *Drug Delivery to the Posterior Segment of the Eye II: Development and Validation of a Simple Pharmacokinetic Model for Subconjunctival Injection*. Journal of Ocular Pharmacology and Therapeutics, 2004. **20**(1): p. 43–53.
6. Lee, T.W.-Y. and J.R. Robinson, *Drug Delivery to the Posterior Segment of the Eye III: The Effect of Parallel Elimination Pathway on the Vitreous Drug Level After Subconjunctival Injection*. Journal of Ocular Pharmacology and Therapeutics, 2004. **20**(1): p. 55–64.
7. Hoang, K.C. and S. Mecozzi, *Aqueous solubilization of highly fluorinated molecules by semifluorinated surfactants*. Langmuir, 2004. **20**(18): p. 7347–7350.
8. Goncalves, E., R.J. Debs, and T.D. Heath, *The effect of liposome size on the final lipid/DNA ratio of cationic lipoplexes*. Biophys J, 2004. **86**(3): p. 1554–63.
9. Croy, S.R. and G.S. Kwon, *The effects of Pluronic block copolymers on the aggregation state of nystatin*. J Control Release, 2004. **95**(2): p. 161–71.

10. Comstock, L.R. and S.R. Rajski, *Efficient Synthesis of Azide-Bearing Cofactor Mimics*. Journal of Organic Chemistry, 2004. **69**(4): p. 1425–1428.
11. Clark, M.D., et al., *Evaluation of liposome-encapsulated oxymorphone hydrochloride in mice after splenectomy*. Comparative Medicine, 2004. **54**(5): p. 558–563.
12. Smith, L.J., et al., *A single dose of liposome-encapsulated oxymorphone or morphine provides long-term analgesia in an animal model of neuropathic pain*. Comparative Medicine, 2003. **53**(3): p. 280–287.

2003

1. Restituyo Jose, A., et al., *Conversion of aryl azides to O-alkyl imidates via modified Staudinger ligation*. Organic letters, 2003. **5**(23): p. 4357–60.
2. Rajski, S.R., L.R. Comstock, and S.G. Petersen, *Progress on the synthesis of functionally diverse aziridine-based cofactor mimetics*. American Association of Colleges of Pharmacy Annual Meeting, 2003. **104**(JUL): p. NIL_0270.
3. Krugner-Higby, L., et al., *Liposome-encapsulated oxymorphone hydrochloride provides prolonged relief of postsurgical visceral pain in rats*. Comp Med, 2003. **53**(3): p. 270–9.

2002

1. Goncalves, E. and T.D. Heath, *The effect of liposome size on lipoplex formation: The relationship between mixing and final lipid: DNA lipoplex ratios*. Biophysical Journal, 2002. **82**(1): p. 536A–536A.
2. Comstock, L.R. and S.R. Rajski, *Expedition synthesis of aziridine-based cofactor mimics*. Tetrahedron, 2002. **58**(30): p. 6019–6026.
3. Bursavich, M.G. and D.H. Rich, *Designing Non-Peptide Peptidomimetics in the 21st Century: Inhibitors Targeting Conformational Ensembles*. Journal of Medicinal Chemistry, 2002. **45**(3): p. 541–558.
4. Amin, K., et al., *Cell association of liposomes with high fluid anionic phospholipid content is mediated specifically by LDL and its receptor, LDLr*. J Pharm Sci, 2002. **91**(5): p. 1233–44.
5. Adams, M.L. and G.S. Kwon, *The effects of acyl chain length on the micelle properties of poly(ethylene oxide)-block-poly(N-hexyl-L-aspartamide)-acyl conjugates*. J Biomater Sci Polym Ed, 2002. **13**(9): p. 991–1006.

2001

1. Lee, T.W.-Y. and J.R. Robinson, *Drug delivery to the posterior segment of the eye: some insights on the penetration pathways after subconjunctival injection*. Journal of Ocular Pharmacology and Therapeutics, 2001. **17**(6): p. 565–572.
2. Amin, K., et al., *LDL induced association of anionic liposomes with cells and delivery of contents as shown by the increase in potency of liposome dependent drugs*. Pharm Res, 2001. **18**(7): p. 914–21.
3. Amin, K. and T.D. Heath, *LDL-induced association of anionic liposomes with cells and delivery of contents - II. Interaction of liposomes with cells in serum-containing medium*. Journal of Controlled Release, 2001. **73**(1): p. 49–57.